Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will collaborate with Humana’s CenterWell Pharmacy to fulfill and deliver prescriptions…
GLP-1s
U.K. regulators have launched a study into a possible genetic link between use of GLP-1s, such as Ozempic, Mounjaro and Wegovy, and acute pancreatitis. Yellow Card Biobank, a joint initiative of Genomics England and the government, is calling for patients…
After three years, only about 1 in 12 individuals taking GLP-1s to treat obesity remained on the therapy, according to a Prime Therapeutics study published on June 25. Prime is owned by 19 Blue Cross and Blue Shield plans and…
Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker alleged that Hims & Hers marketed unauthorized versions of semaglutide, the active…
Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, including the new 12.5 mg and…
Advertisement
Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg reported June 10. Eli Lilly CFO Lucas Montarce…
A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four takeaways:
New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among adolescents, Truveta examined data from 1.2 million children aged 12…
Over the past month, studies have shown Zepbound leads to more weight loss than Wegovy, and GLP-1 drugs may lower obesity-related cancer risk better than bariatric surgery. Here are eight quick updates on the medication class: 1. The percentage of…
In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records. Fair Health also found that, over those…